The gut microbiota modulates glycaemic control and serum metabolite profiles in non-obese diabetic mice

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Greiner, Thomas U ^a   Hyötyläinen, Tuulia ^b,c   Knip, Mikael ^d,e,f,g   Bäckhed, Fredrik ^a,h   Orešič, Matej ^b,c  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b VTT TECHNICAL RESEARCH CENTRE OF FINLAND   (Finland)

^c STENO DIABETES CENTER   (Denmark)

^d UNIVERSITY OF HELSINKI AND HELSINKI UNIVERSITY HOSPITAL   (Finland)

^e UNIVERSITY OF HELSINKI   (Finland)

^f FOLKHÄLSAN RESEARCH CENTER   (Finland)

^g TAMPERE UNIVERSITY HOSPITAL   (Finland)

^h Capital Region   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; GAMMA INTERFERON; GLUCOSE; TRIACYLGLYCEROL; TRICARBOXYLIC ACID; CYTOKINE; GLUCOSE BLOOD LEVEL; INSULIN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CELL INFILTRATION; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; GENETIC RISK; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCEMIC CONTROL; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; INTESTINE FLORA; MASS SPECTROMETRY; METABOLOMICS; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; SEX DIFFERENCE; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ANIMAL; AUTOIMMUNE DISEASE; BLOOD; EXPERIMENTAL DIABETES MELLITUS; FEMALE; GAS CHROMATOGRAPHY; GLUCOSE TOLERANCE TEST; IMMUNOLOGY; INFLAMMATION; INTESTINE; METABOLISM; MICROBIOLOGY; MICROFLORA; NONOBESE DIABETIC MOUSE; PANCREAS ISLET BETA CELL;

MUS;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; BLOOD GLUCOSE; CHROMATOGRAPHY, GAS; CYTOKINES; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; FEMALE; GLUCOSE TOLERANCE TEST; INFLAMMATION; INSULIN; INSULIN-SECRETING CELLS; INTESTINES; METABOLOMICS; MICE; MICE, INBRED NOD; MICROBIOTA;

EID: 84911928672     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0110359     Document Type: Article

References (44)

1. Lernmark A, Larsson HE (2013) Immune therapy in type 1 diabetes mellitus. Nat Rev Endocrinol 9: 92-103.
2. Patterson CC, Dahlquist GG, Gyürü s E, Green A, Soltész G (2009) Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet 373: 2027-2033.
3. Gale EA, Gillespie KM (2001) Diabetes and gender. Diabetologia 44: 3-15.
4. Barnett AH, Eff C, Leslie RD, Pyke DA (1981) Diabetes in identical twins. A study of 200 pairs. Diabetologia 20: 87-93.
5. Kaprio J, Tuomilehto J, Koskenvuo M, Romanov K, Reunanen A, et al. (1992) Concordance for type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes mellitus in a population-based cohort of twins in Finland. Diabetologia 35: 1060-1067.
6. Knip M, Veijola R, Virtanen SM, Hyöty H, Vaarala O, et al. (2005) Environmental triggers and determinants of type 1 diabetes. Diabetes 54: S125-136.
7. Strachan DP, Taylor EM, Carpenter RG (1996) Family structure, neonatal infection, and hay fever in adolescence. Arch Dis Child 74: 422-426.
8. Ben Nasr M, D'Addio F, Usuelli V, Tezza S, Abdi R, et al. (2014) The rise, fall, and resurgence of immunotherapy in type 1 diabetes. Pharmacol Res.
9. Herold KC, Vignali DA, Cooke A, Bluestone JA (2013) Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nat Rev Immunol 13: 243-256.
10. Vergani A, D'Addio F, Jurewicz M, Petrelli A, Watanabe T, et al. (2010) A novel clinically relevant strategy to abrogate autoimmunity and regulate alloimmunity in NOD mice. Diabetes 59: 2253-2264.
11. Bjorksten B (2009) Disease outcomes as a consequence of environmental influences on the development of the immune system. Curr Opin Allergy Clin Immunol 9: 185-189.
12. Greiner T, Backhed F (2011) Effects of the gut microbiota on obesity and glucose homeostasis. Trends Endocrinol Metab 22: 117-123.
13. Karlsson FH, Tremaroli V, Nookaew I, Bergstrom G, Behre CJ, et al. (2013) Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 498: 99-103.
14. Qin J, Li Y, Cai Z, Li S, Zhu J, et al. (2012) A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490: 55-60.
15. Giongo A, Gano KA, Crabb DB, Mukherjee N, Novelo LL, et al. (2011) Toward defining the autoimmune microbiome for type 1 diabetes. ISME J 5: 82-91.
16. de Goffau MC, Luopajarvi K, Knip M, Ilonen J, Ruohtula T, et al. (2013) Fecal Microbiota Composition Differs Between Children With beta-Cell Autoimmunity and Those Without. Diabetes 62: 1238-1244.
17. Kilkkinen A, Virtanen SM, Klaukka T, Kenward MG, Salkinoja-Salonen M, et al. (2006) Use of antimicrobials and risk of type 1 diabetes in a population-based mother-child cohort. Diabetologia 49: 66-70.
18. Koren O, Goodrich JK, Cullender TC, Spor A, Laitinen K, et al. (2012) Host remodeling of the gut microbiome and metabolic changes during pregnancy. Cell 150: 470-480.
19. Wen L, Ley RE, Volchkov PY, Stranges PB, Avanesyan L, et al. (2008) Innate immunity and intestinal microbiota in the development of type 1 diabetes. Nature 455: 1109-1113.
20. Calcinaro F, Dionisi S, Marinaro M, Candeloro P, Bonato V, et al. (2005) Oral probiotic administration induces interleukin-10 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse. Diabetologia 48: 1565-1575.
21. Markle JG, Frank DN, Mortin-Toth S, Robertson CE, Feazel LM, et al. (2013) Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity. Science 339: 1084-1088.
22. Oresic M, Simell S, Sysi-Aho M, Nanto-Salonen K, Seppanen-Laakso T, et al. (2008) Dysregulation of lipid and amino acid metabolism precedes islet autoimmunity in children who later progress to type 1 diabetes. J Exp Med 205: 2975-2984.
23. Sysi-Aho M, Ermolov A, Gopalacharyulu PV, Tripathi A, Seppanen-Laakso T, et al. (2011) Metabolic regulation in progression to autoimmune diabetes. PLoS Comput Biol 7: e1002257.
24. Castillo S, Mattila I, Miettinen J, Oresic M, Hyotylainen T (2011) Data analysis tool for comprehensive two-dimensional gas chromatography/time-of-flight mass spectrometry. Anal Chem 83: 3058-3067.
25. Nygren H, Seppanen-Laakso T, Castillo S, Hyotylainen T, Oresic M (2011) Liquid Chromatography-Mass Spectrometry (LC-MS)-Based Lipidomics for Studies of Body Fluids and Tissues. Methods Mol Biol 708: 247-257.
26. Pluskal T, Castillo S, Villar-Briones A, Oresic M (2010) MZmine 2: Modular framework for processing, visualizing, and analyzing mass spectrometry-based molecular profile data. BMC Bioinformatics 11: 395.
27. Saeed AI, Sharov V, White J, Li J, Liang W, et al. (2003) TM4: a free, opensource system for microarray data management and analysis. Biotechniques 34: 374-378.
28. Anderson MS, Bluestone JA (2005) The NOD mouse: a model of immune dysregulation. Annu Rev Immunol 23: 447-485.
29. Backhed F, Ding H, Wang T, Hooper LV, Koh GY, et al. (2004) The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A 101: 15718-15723.
30. Caesar R, Reigstad CS, Backhed HK, Reinhardt C, Ketonen M, et al. (2012) Gut-derived lipopolysaccharide augments adipose macrophage accumulation but is not essential for impaired glucose or insulin tolerance in mice. Gut 61: 1701-1707.
31. Velagapudi VR, Hezaveh R, Reigstad CS, Gopalacharyulu P, Yetukuri L, et al. (2010) The gut microbiota modulates host energy and lipid metabolism in mice. J Lipid Res 51: 1101-1112.
32. Alam C, Bittoun E, Bhagwat D, Valkonen S, Saari A, et al. (2011) Effects of a germ-free environment on gut immune regulation and diabetes progression in non-obese diabetic (NOD) mice. Diabetologia 54: 1398-1406.
33. Bach J-F (2002) The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 347: 911-920.
34. van Belle TL, Coppieters KT, von Herrath MG (2011) Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev 91: 79-118.
35. Sommer F, Backhed F (2013) The gut microbiota-masters of host development and physiology. Nat Rev Microbiol 11: 227-238.
36. Fiorina P, Vergani A, Dada S, Jurewicz M, Wong M, et al. (2008) Targeting CD22 reprograms B-cells and reverses autoimmune diabetes. Diabetes 57: 3013-3024.
37. Shoda LK, Young DL, Ramanujan S, Whiting CC, Atkinson MA, et al. (2005) A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity 23: 115-126.
38. Fujihira K, Nagata M, Moriyama H, Yasuda H, Arisawa K, et al. (2000) Suppression and acceleration of autoimmune diabetes by neutralization of endogenous interleukin-12 in NOD mice. Diabetes 49: 1998-2006.
39. Trembleau S, Penna G, Gregori S, Giarratana N, Adorini L (2003) IL-12 administration accelerates autoimmune diabetes in both wild-type and IFN-gamma- deficient nonobese diabetic mice, revealing pathogenic and protective effects of IL-12-induced IFN-gamma. J Immunol 170: 5491-5501.
40. Yang Z, Chen M, Wu R, Fialkow LB, Bromberg JS, et al. (2002) Suppression of autoimmune diabetes by viral IL-10 gene transfer. J Immunol 168: 6479-6485.
41. Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, et al. (2011) Metabolite profiles and the risk of developing diabetes. Nat Med 17: 448-454.
42. Floegel A, Stefan N, Yu Z, Muhlenbruch K, Drogan D, et al. (2013) Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach. Diabetes 62: 639-648.
43. Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, et al. (2009) A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab 9: 311-326.
44. Gall WE, Beebe K, Lawton KA, Adam KP, Mitchell MW, et al. (2010) alphahydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population. PLoS ONE 5: e10883.